Pancreatic ductal carcinoma (PDC) is one of the most lethal human cancers. Pancreatic ductal carcinomas are usually unresectable (80--90%) at the time of diagnosis, despite recent progress in imaging modalities. Gemcitabine (GEM) has been the standard first-line chemotherapy agent for unresectable PDC ([@bib3]). Only 10--20% of patients with PDC are candidates for curative resection ([@bib17]). Even if curative resection is performed, the postoperative 5-year survival rate is only 15--25% because of a high rate of recurrence ([@bib24]). Recently, two randomised clinical phase III trials of adjuvant chemotherapy (AC) for PDC showed significant increases in overall survival (OS) and disease-free survival (DFS) ([@bib19]; [@bib20]). Therefore, AC is important for patients with PDC. If GEM could be appropriately and selectively administered to patients with GEM sensitivity based on the expression of genes in the tumour, maximal chemotherapy efficacy could be achieved without subjecting GEM-resistant patients to unnecessary side effects.

Recent investigations using cell lines or surgical specimens have revealed that the expression of several genes may be predictors of GEM efficacy in GEM-treated patients. Such GEM efficacy predictor genes include human equilibrative nucleoside transporter 1 (*hENT1*), the major mediator of GEM uptake in human cells ([@bib7]); GEM-metabolism-related enzymes such as deoxycitidine kinase (*dCK*) ([@bib16]); GEM resistance-related enzymes such as ribonucleoside reductase 1 (*RRM1*) ([@bib18]), ribonucleoside reductase 2 (*RRM2*) ([@bib12]) and *Notch3* ([@bib26]), which is related to GEM-induced caspase-mediated apoptosis. [@bib1] and [@bib12] demonstrated that levels of expression of these genes correlated with GEM sensitivity in patients with unresectable PDC. The aim of this study was to determine a predictive indicator of survival and GEM sensitivity in GEM-treated patients with unresectable PDC by examining gene expression in pre-treated tissue biopsy samples obtained by endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA).

Materials and Methods
=====================

Patients
--------

The study included 185 consecutive patients in whom pancreatic masses had been identified by abdominal ultrasound or computed tomography and who underwent EUS-FNA at Hokkaido Hospital between October 2007 and September 2010. Subjects were excluded if they had an extrapancreatic mass, tumour histology other than ductal adenocarcinoma or preoperative evidence of resectable PDC. Finally, the analysed population comprised a consecutive series of 71 patients ([Figure 1](#fig1){ref-type="fig"}).

EUS-FNA procedure
-----------------

Endoscopic ultrasound was performed using an oblique forward-viewing electronic linear scanning video echoendoscope equipped with an elevator and a 3.7-mm-diameter working channel (GF-UCT240-AL5; Olympus Medical Systems Co., Ltd, Tokyo, Japan). The echoendoscope was connected to a processor with a colour Doppler function (SSD-5500; Hitachi-Aloka Medical., Ltd, Tokyo, Japan). EUS-FNA was performed before treatment, as described previously ([@bib13]). Briefly, the lesions were identified using B-mode imaging. The absence of vessels in the target area was confirmed with the colour Doppler mode. After determination of an adequate angle to the tumour, an aspiration needle was introduced into the lesion. While suction was applied through the catheter connected to the needle using a 20-ml syringe, the needle was moved back and forth 10--20 times within the tumour. Negative pressure was released before the needle was removed from the lesion. To obtain sufficient tissue for RNA extraction and pathological diagnosis, several biopsy specimens were collected from each tumour by EUS-FNA using 22-G aspiration needles (EchoTip Ultra; Cook Japan, Tokyo, Japan). A cytologist immediately examined the specimens for cancer cells using part of the obtained tissue. We performed an additional one to two punctures after conventional diagnostic puncture to obtain adequate tissue for RNA extraction.

mRNA extraction
---------------

Tissue and blood collected from the obtained specimens were examined for confirmation of carcinoma cells by an on-site cytologist. The remaining tissue was instantly transferred to a 1.5-ml micro test tube (Eppendorf, Saxony, Germany) and frozen at −80 °C until use. The test tube that was used to inactivate the RNase was rinsed with 0.1 𝒩 NaOH/1 mℳ EDTA and diethylpyrocarbonate, and was stored at room temperature. Tissue samples were crushed in a mortar and placed on ice for RNA detection.Total RNA was isolated using the TRIzol Reagent method. Total RNA concentration was determined by spectrophotometer (NanoDrop2000c; Thermo, Tokyo, Japan), and 1 *μ*g total RNA was reverse transcribed using a Transcript First Strand cDNA Synthesis kit (Roche Diagnostics KK, Tokyo, Japan). Quantification of the target cDNA and an internal reference gene (*β2-microglobulin*, *β2M*) was conducted by quantitative real-time reverse transcription--polymerase chain reaction (qRT--PCR).

qRT--PCR
--------

We designed specific primers using Primer-BLAST (NCBI, <http://www.ncbi.nlm.nih.gov/tools/primer-blast/>). The following primers were used for real-time PCR: *dCK* -- forward primer, 5′-TCAAGCCACTCCAGAGACATGCTT-3′ reverse primer, 5′-TGTCCTATGCAGGAGCCAGCTTTCA-3′ *hENT1* -- forward primer, 5′-GGCCCAAGAAAGTGAAGCCA-3′ reverse primer, 5′-ACCACTCAGGATCACCCCTG-3′ *RRM1* -- forward primer, 5′-TCAAGGTGGGAACAAGCGTC-3′ reverse primer, 5′-CGCTGCTCTTCCTTTCCTGT-3′ *RRM2* -- forward primer, 5′-ACGGAGCCGAAAACTAAAGCAGCT-3′ reverse primer, 5′-AGAGTCCACCTCCTCGGCG-3′ and *Notch3* -- forward primer, 5′-TCCAGATTCTCATCCGAAACCGCT-3′ reverse primer, 5′-GGGTCTCCTCCTTGCTATCCTGCAT-3′. qRT--PCR was performed using a Rotor-Gene Q (Qiagen, Hilden, Germany) for 40 cycles at 95 °C for 5 s and 60 °C for 10 s using a SYBR Green PCR Master Mix (Qiagen), according to the manufacturer\'s instructions. Quantification was performed using the relative standard curve method. The standard curve was created automatically by Rotor-Gene Q by plotting the threshold cycle (*C*~t~) against each input amount (containing 10^7^, 10^6^, 10^5^, 10^4^, 10^3^, 10^2^ and 10^1^ copies) of standard plasmid DNA. The standard plasmid DNA was created by direct cloning using a TA cloning vector and the PCR product generated using the specific primers described above and checked by sequencing. The correlation coefficient determined by linear regression (*r*) for each standard curve was \>0.990. The relative amount of each unknown sample was calculated by linear regression analysis from the respective standard curve. A relative target gene expression value for *β2M* was used as an internal reference gene.

Target mRNA
-----------

Expressions of *dCK*, *hENT1*, *RRM1*, *RRM2* and *Notch3* were examined as genetic predictive markers associated with GEM transport and metabolism.

Statistical analyses
--------------------

The primary end point was survival in GEM-treated patients with unresectable PDC according to the expression levels of the examined genes. The cutoff for analysis of survival was 30 April 2011. The secondary end point was time to progression (TTP) in the patients. Survival and TTP curves were estimated using the Kaplan--Meier technique. Differences between the survival curves and those between TTP curves were assessed using the log-rank test. The Cox proportional hazard regression model was used for multivariate analyses of survival and for estimating hazard ratios (HRs) with 95% confidence intervals (CIs). The *χ*^2^ test was used to compare proportions. Statistical analyses were performed after dichotomising subgroups as follows: *hENT1* low *vs* high, *dCK* low *vs* high, *RRM1* low *vs* high, *RRM2* low *vs* high and *Notch3* low *vs* high. The thresholds were determined by the median of the mRNA expression in each of the 71 patients.

A value of *P*\<0.05 was considered to indicate statistical significance. All statistical analyses were performed using JMP ver. 9.0 software (SAS Institute, Cary, NC, USA).

This study was carried out in accordance with the Institutional Review Board guidelines (Hokkaido University Hospital, Sapporo, Japan; clinical research approval number 010-0152), and written informed consent was obtained from all patients.

Results
=======

Patient characteristics
-----------------------

The clinical characteristics of the 56 patients who received GEM-based chemotherapy (GEM population) and the 15 who did not (non-GEM population) are shown in [Table 1](#tbl1){ref-type="table"}. There was no significant difference between the groups for all clinical characteristics other than age (\<69 years *vs* \>68 years =69 *vs* 68, *P*=0.023).

mRNA expression
---------------

Total RNA was successfully extracted from all specimens from the patients. The mean RNA concentration was 124±85 ng *μ*l^−1^ (mean±s.d.) (range 13.2--478.8). The mean *dCK*, *hENT1*, *RRM1*, *RRM2* and *Notch3* mRNA levels relative to the *β2M* internal reference gene were 63±79 (range 0--546), 590±620 (5--3178), 576±3973 (0.3--41 508), 757±2195 (5--13 286), 242±629 (0--4490), respectively.

Association between OS and mRNA expression levels in patients treated with GEM
------------------------------------------------------------------------------

Patients with low *Notch3* mRNA levels tended to have a better prognosis than those with high *Notch3* mRNA level (low *vs* high=23.6 *vs* 19.3 months, *P*=0.068). However, there were no tendencies and no significant differences in OS between patients with low and high mRNA levels of *hENT1* (low *vs* high=23.6 *vs* 20 months, *P*=0.302), *dCK* (low *vs* high=23.6 *vs* 20 months, *P*=0.930), *RRM1* (low *vs* high=27.7 *vs* 19.3 months, *P*=0.215) and *RRM2* (low *vs* high=20 *vs* 27.7 months, *P*=0.520) ([Figure 2](#fig2){ref-type="fig"}).

Association between TTP and mRNA expression levels in the GEM-treated population
--------------------------------------------------------------------------------

Patients with high *hENT1* (low *vs* high=15 *vs* 21 months, *P*=0.051) or low *Notch3* (low *vs* high=31 *vs* 21 months, *P*=0.051) mRNA levels had longer TTP than patients with low *hENT1* or high *Noch3* mRNA levels. In contrast, there were no differences in TTP between patients with low and high mRNA levels of *dCK* (*P*=0.162), *RRM1* (*P*=0.200) and *RRM2* (*P*=0.225) ([Figure 3](#fig3){ref-type="fig"}).

Factors associated with OS of all patients with unresectable pancreatic cancer
------------------------------------------------------------------------------

Multivariate analysis for survival of all patients with unresectable PDC based on the Cox proportional hazard model was performed on all parameters described in [Table 2](#tbl2){ref-type="table"}. Survival was significantly associated with *Notch3* expression levels (HRs, high *vs* low=1.00 *vs* 0.0255, *P*=0.0094) ([Table 2](#tbl2){ref-type="table"}). Although a significant difference was not observed, a tendency for the prognosis to be long was seen in patients with high *hENT1* expression levels (HRs, high *vs* low=1.00 *vs* 29.9 *P*=0.074). Interaction tests for GEM administration and *hENT1* or *Notch3* mRNA expression levels were statistically significant (*P*=0.0054 and 0.0047, respectively). Furthermore, we examined predictors of TTP in all patients. Multivariate analysis for TTP based on the Cox proportional hazard model was also performed on all parameters described in [Table 3](#tbl3){ref-type="table"}. A high *hENT1* expression level was significantly associated with a long TTP (high *vs* low=1.00 *vs* 29.9; *P*=0.039) ([Table 3](#tbl3){ref-type="table"}).

Discussion
==========

In this retrospective study, we demonstrated that the expression levels of the *hENT1* and *Notch3* genes are promising predictive markers for GEM responsiveness in patients with unresectable PDC. The possibility that *Notch3* was a prognostic predictive factor was considered on the basis of the results shown in [Table 2](#tbl2){ref-type="table"}. Furthermore, the possibility that *hENT1* was a predictive of GEM responsiveness was suggested by the results shown in [Table 3](#tbl3){ref-type="table"}. Interaction tests involving these two genes supported the possibility that they are predictive of GEM responsiveness.

Human equilibrative nucleoside transporter 1 is a major GEM transporter that is overexpressed in pancreatic cancer cells ([@bib10]). The expression of *hENT1* mRNA in resected specimens from patients with pancreatic cancer is associated with long OS, DFS and time to disease progression ([@bib11]; [@bib7]; [@bib15]). Our results of multivariable analysis and interaction testing are compatible with the findings of previous reports. However, owing to the limitation represented by the small non-GEM-treated population, we could not compare Kaplan--Meier curves of the non-GEM population *vs* those of the GEM-treated population.

*Notch3* plays important roles in the control of cell extracellular interactions, such as spreading, migration, motility and survival in pancreatic cancer cells ([@bib5]). The Notch signalling pathway is involved in the acquisition of the epithelial--mesenchymal transition (EMT) phenotype related to invasion of pancreatic cancer cells, and downregulation of Notch signalling is associated with decreased invasive behaviour of pancreatic cancer cells, followed by partial reversal of the EMT phenotype ([@bib25]). In previous reports regarding resected PDC specimens, *Notch3* was frequently overexpressed in PDC lesions compared with normal pancreatic ductal tissue ([@bib6]). Meanwhile, nuclear *Notch3* expression was clinically correlated with a lower OS time of PDC patients ([@bib6]) and also other carcinomas such as ovarian carcinoma ([@bib21]). In addition, it was reported that suppression of *Notch3* expression decreased the average half-maximal inhibitory concentration (IC~50~) of GEM in pancreatic cell lines ([@bib26]). Thus, there may be at least two pathways for the GEM effect: suppression of *Notch3* expression by GEM and amplification of the GEM effect through the suppression of *Notch3*.

To date, there has been no report of the relationship between the effectiveness of GEM and *Notch3* mRNA expression in the clinical course of PDC. For the first time, our results using pre-treated EUS-FNA specimens suggest that *Notch3* is a promising informative biomarker for predicting the effectiveness of GEM and GEM sensitivity in patients with unresectable PDC. Using Kaplan--Meier analysis of OS and TTP and multivariate analysis for OS, our expression data and clinical results might be used to address the results of patients with low *Notch3* mRNA levels compared to patients with high levels. However, further study in more patients is needed to confirm this correlation.

Endoscopic ultrasound-guided fine-needle aspiration is widely used as a cytological and histological sample collection tool for pancreatic cancer ([@bib23]; [@bib14]), and there have been some reports of oncogene analysis in pancreatic cancer using EUS-FNA samples ([@bib22]; [@bib2]; [@bib14]; [@bib1]). The reliability of tests based on tissue or cell extracts is often dependent on the relative abundance of the target cell population. Moreover, sampling errors or a large number of 'contaminating cells\' can lead to false-negative results ([@bib8]). This is likely why [@bib9] were unable to detect significant differences in mRNA levels among whole-cell pellet samples; however, they could distinguish higher and lower expression of each gene among neoplastic cell samples by microdissection. In this, we could distinguish higher and lower expression of genes by selection of white tissue on site, although we used total RNA isolated from EUS-FNA tissue samples without microdissection. It may be important to trim white tissue for high-quality RNA analysis, although there is no evidence to support this. In addition, some reports suggest that flow cytometry and cytogenetic analysis or improvement of diagnostic accuracy using specimens of EUS-FNA could be achieved using a thick 19-G needle instead of a 22- or 25-G needle puncture ([@bib27]). Therefore, further development of methods for sample collection and processing are required to improve wide genetic analysis of EUS-FNA specimens.

If GEM sensitivity could be predicted using specimens collected by EUS-FNA at the same time as pathological diagnosis, the appropriate anticancer agents such as oxaliplatin, irinotecan, fluorouracil and leucovorin (FOLFIRINOX) could be selected ([@bib4]). Furthermore, based on the results of RNA analyses of EUS-FNA specimens, the appropriate preoperative neoadjuvant chemotherapy could be administered.

There are several limitations to our study. One is that the sample size and observation period were not sufficient, and the other is that this was a retrospective and single centre study. To address these issues, a large-scale, multicentre prospective study is needed.

In conclusion, based on genetic analysis of EUS-FNA tissue samples, our data suggest that *hENT1* and *Notch3* mRNA expression levels are promising novel and informative biomarkers for predicting and monitoring G sensitivity in patients with unresectable PDC.
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![**Flow diagram of the study participants.**](bjc2013108f1){#fig1}

![**Kaplan--Meier curves of survival in the GEM-treated population according to each mRNA expression level.** Each mRNA expression level was assigned to high or low using the median as a threshold.](bjc2013108f2){#fig2}

![**Kaplan--Meier curves of progression-free survival in the GEM-treated population according to each mRNA expression level.** Each mRNA expression level was assigned to high or low using the median as a threshold.](bjc2013108f3){#fig3}

###### Clinical characteristics of patients

                                               **GEM population (*****n*****=56)**   **Non-GEM population (*****n*****=15)**   ***P*****-value** ***χ*****2 test**
  -------------------------------------------- ------------------------------------- ----------------------------------------- -------------------------------------
  Median age in years (range)                  69 (37--88)                           68 (49--84)                               0.023
  \<69 years                                   24 (43%)                              8 (53%)                                    
  \>68 years                                   32 (57%)                              7 (47%)                                    
  **Sex**                                                                                                                      
  Male                                         26 (46.4%)                            9 (60%)                                   0.349
  Female                                       30 (53.6%)                            6 (40%)                                    
  **Location**                                                                                                                 
  Ph                                           24 (42.9%)                            6 (40%)                                   0.842
  Pb and Pt                                    32 (57.1%)                            9 (60%)                                    
  **UICC TNM 7th f-stage**                                                                                                     
  Stage III                                    17 (30.4%)                            3 (20%)                                   0.346
  Stage IV                                     39 (69.6%)                            12 (80%)                                   
  **Performance status**                                                                                                       
  0                                            49 (87.5%)                            11 (73.3%)                                0.201
  1--3                                         7 (12.5%)                             4 (26.7%)                                  
  **Comorbidities**                                                                                                            
  Some                                         39 (69.6%)                            11 (73.3%)                                0.779
  None                                         17 (30.4%)                            4 (26.7%)                                  
  **GEM efficacy**                                                                                                             
  CR                                           0 (0%)                                                                           
  PR                                           1 (1.8%)                                                                         
  SD                                           34 (60.7%)                                                                       
  PD                                           21 (37.5%)                                                                       
  No. of chemotherapy cycles, median (range)   4 (1--31)                                                                        

Abbreviations: CR=complete response; GEM=gemcitabine; Pb=body of the pancreas; PD=progressive disease; Ph=head of the pancreas; PR=partial response; Pt=tail of the pancreas; SD=stable disease; TNM=tumour node metastasis; UICC=Unio Internationalis Contra Cancrum.

###### Multivariate analysis of survival in patients with unresectable PDC

                              **Multivariate analysis (survival)**                                  
  -------------------------- -------------------------------------- ------------ ------------------ --------
  **Age (years)**                                                                                   
  \<69/⩾69                                   32/39                     1/3.83        0.44--68.0      0.229
  **Sex**                                                                                           
  Female/male                                36/35                    1/0.154       0.011--1.12       0.06
  **Location**                                                                                      
  Ph/Pb and Pt                               30/41                     1/7.31        0.29--728       0.244
  **UICC TNM 7th f-stage**                                                                          
  III/IV                                     21/50                    1/0.0384    0.000347--0.734    0.0275
  **Performance status**                                                                            
  0/1--3                                     65/11                   1/0.000127    0--117 429 839    0.995
  **Comorbidities**                                                                                 
  Some/none                                  50/21                    1/0.0557     0.0007--0.682     0.020
  **GEM-treated**                                                                                   
  Yes/no                                     56/15                    1/0.209      0.00204--8.75     0.419
  **hENT1**                                                                                         
  High/low                                   33/38                     1/29.9       0.730--2918      0.074
  **dCK**                                                                                           
  High/low                                   38/33                    1/4.098       0.371--61.8      0.236
  **RRM1**                                                                                          
  High/low                                   37/34                    1/0.515       0.0174--20.1     0.702
  **RRM2**                                                                                          
  High/low                                   39/32                     1/1.64       0.117--56.0      0.733
  **Notch3**                                                                                        
  High/low                                   43/28                    1/0.0255    0.0000483--0.503   0.0094

Abbreviations: CI=confidence interval; dCK=deoxycitidine kinase; GEM=gemcitabine; hENT1=human equilibrative nucleoside transporter 1; HR=hazard ratio; N=number; Pb=body of the pancreas; PDC=pancreatic ductal carcinoma; Ph=head of the pancreas; Pt=tail of the pancreas; RRM1=ribonucleoside reductase 1; RRM2=ribonucleoside reductase 2.

###### Multivariate analysis of progression of disease in the GEM population

                              **Multivariate analysis (progression)**                             
  -------------------------- ----------------------------------------- --------- ---------------- -------
  **Age (years)**                                                                                 
  \<69/⩾69                                     29/27                    1/1.42     0.0427--54.1    0.836
  **Sex**                                                                                         
  Female/male                                  30/26                    1/0.396    0.0121--5.62    0.501
  **Location**                                                                                    
  Ph/Pb and Pt                                 24/32                    1/1.35     0.0137--3848    0.908
  **UICC TNM 7th f-stage**                                                                        
  III/IV                                       18/38                    1/0.687   0.000491--50.7   0.873
  **Performance status**                                                                          
  0/1--3                                       49/7                     1/54.7    0.777--14 312    0.064
  **Comorbidities**                                                                               
  Some/none                                    39/17                    1/0.281   0.00541--3.94    0.374
  **TMs decline**                                                                                 
  \<50%/⩾50%                                   32/24                    1/0.906    0.0558--13.0    0.939
  **hENT1**                                                                                       
  High/low                                     30/26                    1/29.9      1.13--8605     0.039
  **dCK**                                                                                         
  High/low                                     30/26                    1/0.199   0.00503--2.70    0.238
  **RRM1**                                                                                        
  High/low                                     32/24                    1/0.180   0.00187--3.53    0.278
  **RRM2**                                                                                        
  High/low                                     35/21                    1/4.63      0.155--641     0.393
  **Notch3**                                                                                      
  High/low                                     38/18                    1/0.233   0.000862--8.00   0.460

Abbreviations: CI=confidence interval; dCK=deoxycitidine kinase; GEM=gemcitabine; hENT1=human equilibrative nucleoside transporter 1; HR=hazard ratio; N=number; Pb=body of the pancreas; Ph=head of the pancreas; Pt=tail of the pancreas; RRM1=ribonucleoside reductase 1; RRM2=ribonucleoside reductase 2; TMs=tumour markers.
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